ArticleInternational journal of nanomedicine2025
Innovative Dual Therapy: Magnesium Oxide Nanoparticles and Royal Jelly for Parotid Gland Protection in Diabetic Male Rats.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Nanoparticles and natural products have gained attention for their beneficial properties, but limited studies exist on the co-administration of these two therapeutic agents. In this study, both magnesium oxide nanoparticles (MgO NPs) and royal jelly (RJ) were evaluated for their protective potential against parotid gland damage in induced diabetic rats through the investigation of their antidiabetic, antioxidative, and anti-inflammatory effects. Material and Methods: 64 male rats were divided into 8 groups: control group, MgO NPs treated group (300mg/kg/day), RJ treated group (100mg/kg/day), streptozotocin-induced diabetic group, diabetic group and concomitant MgO NPs, diabetic group and concomitant RJ, diabetic group and co-administration of both MgO NPs and RJ, and diabetic group and concomitant metformin (100mg/kg/day). After 8 weeks, the rats of all groups were anaesthetized, and blood was drawn to estimate different diabetic parameters. Saliva was collected to determine the salivary parameters. The parotid glands were excised and cut into pieces, where half was frozen for further biochemical investigations (oxidative stress and inflammatory markers) and the other assessed for histological and immunohistochemical changes. Results: The administration of either MgO NPs or RJ to diabetic rats significantly improved the diabetic parameters and nearly restored the salivary and oxidative stress parameters to control values. There was a significant improvement in the histological and immunohistochemical alterations in the parotid gland. Conclusion: Both MgO NPs and RJ were effective in protecting the parotid gland from damage in the diabetic rats. These effects were even more profound when the two agents were administered together.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.